Toripalimab, the first domestic anti-tumor PD-1 antibody in China, is a selective, recombinant, humanized monoclonal antibody that targets PD-1. By binding to PD-1, it inhibits interactions with its ligands, demonstrating primary anti-tumor efficacy in various tumors, including melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma, and urothelial carcinoma [1].